# US 12,109,270 B2 · Rifaximin complexes > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,109,270 B2 - Document ID: US12109270B2 - Status: Granted - Kind: B2 - Application number: 17/862,491 - Filed: 2022-07-12 - Published: 2023-06-15 - Granted: 2024-10-08 - Earliest claimed: 2008-12-10 - Assignees: Cipla Limited - Applicants: Cipla Limited - Inventors: Maruti Ganpati Ghagare; Sunilkumar Parasnath Saroj; Dharmaraj Ramachandra Rao; Rajendra Narayanrao Kankan - Web page: https://patentgrep.com/patent/US12109270B2 ## CPC - A61K 47/40: Cyclodextrins; Derivatives thereof - A61K 9/2095: {Tabletting processes} - A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles - A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline - A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone} - A61K 47/58: obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin - A61K 47/6951: {using cyclodextrin (cyclodextrins used as simple excipients A61K47/40)} - A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system - A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants - A61P 1/12: Antidiarrhoeals - A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes - A61P 9/12: Antihypertensives - A61P 13/08: of the prostate - A61P 31/04: Antibacterial agents - B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract There is provided a complex comprising rifaximin and a complexing agent, wherein the complexing agent is a polyvinyl pyrrolidone (PVP) or a cyclodextrin. There is also provided a process for preparing the complex, a pharmaceutical composition including the complex and therapeutic uses of the complex. ## Claims ### Claim 1 A method of treating bowel disorders, the method comprising: administering to a patient a therapeutically effective amount of a complex comprising rifaximin and a complexing agent, wherein the complex is in an amorphous form and exhibits enhanced solubility compared to a physical mixture of rifaximin and the complexing agent. ### Claim 2 (depends on 1) The method of claim 1, wherein the complex is a component of a tablet, a pellet, or a capsule. ### Claim 3 (depends on 1) The method of claim 1, wherein the bowel disorder is travelers' diarrhea. ### Claim 4 (depends on 1) The method of claim 1, wherein the bowel disorder is a bowel disease. ### Claim 5 (depends on 1) The method of claim 1, wherein the bowel disorder is irritable bowel syndrome, Crohn's disease, chronic pancreatitis, pancreatic insufficiency and/or colitis. ### Claim 6 (depends on 1) The method of claim 1, wherein the bowel disorder is microbe associated diarrhea. ### Claim 7 (depends on 1) The method according to claim 1, wherein the ratio of rifaximin to complexing agent ranges from 20:1 to 1:20 w/w. ### Claim 8 (depends on 1) The method according to claim 1, wherein the ratio of rifaximin to complexing agent ranges from 10:1 w/w to 1:2 w/w. ### Claim 9 (depends on 1) The method according to claim 1, wherein the rifaximin complex is administered with one or more pharmaceutically acceptable excipients. ### Claim 10 A method of treating bowel disorders, the method comprising: administering to a patient a therapeutically effective amount of a complex comprising rifaximin and a complexing agent, wherein the complex is in an amorphous form and exhibits enhanced solubility compared to a physical mixture of rifaximin and the complexing agent, the complex is a component of a tablet, and the rifaximin complex is administered with one or more pharmaceutically acceptable excipients. ### Claim 11 A method of treating bowel disorders, the method comprising: administering to a patient a therapeutically effective amount of a complex comprising rifaximin and a complexing agent, wherein the complex is in an amorphous form and exhibits enhanced solubility compared to a physical mixture of rifaximin and the complexing agent, the complex is a component of a tablet or a capsule, the bowel disorder is a bowel disease, and the rifaximin complex is administered with one or more pharmaceutically acceptable excipients. ### Claim 12 A method of treating bowel disorders, the method comprising: administering to a patient a therapeutically effective amount of a complex comprising rifaximin and a complexing agent, wherein the complex is in an amorphous form and exhibits enhanced solubility compared to a physical mixture of rifaximin and the complexing agent, the complex is a component of a tablet or a capsule, the bowel disorder is microbe associated diarrhea, and the rifaximin complex is administered with one or more pharmaceutically acceptable excipients.